Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
EU OKs Roche acquisition of Syntex, clearing a major regulatory hurdle for the $5.3 billion deal.
FTC consent order addressing antitrust concerns in Roche's $5.3 billion acquisition of Syntex Corporation, requiring certain divestitures to preserve…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Roche Holding acquired Syntex Corporation for $5.3 billion ($24/share in cash), making Roche the fourth-largest pharmaceutical company in the world. The deal strengthened Roche's US presence and added Syntex's anti-inflammatory and hormonal drug portfolio.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Syntex Corporation (this deal) | 1994 | $5.3B | 59 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 1994 deals · Roche Holding AG deals · Dermatology deals